A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs ONO 7475 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 10 Jan 2019 Planned End Date changed from 10 Nov 2019 to 8 Mar 2021.
- 10 Jan 2019 Planned primary completion date changed from 15 Jan 2019 to 18 Dec 2019.
- 31 Aug 2018 Biomarkers information updated